Gut hormones and endothelial dysfunction in patients with obesity and diabetes

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue 3, 2014, Pages 433-436

  Iantorno, M ^a   Campia, U ^b   Di Daniele, N ^c   Nistico S ^d   Forleo, G B ^c   Cardillo, C ^e   Tesauro, M ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MedStar Cardiovascular Research Network   (United States)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

Diabetes; Endothelial function; Gut hormones; Obesity

Indexed keywords

ENDOTHELIN 1; GASTROINTESTINAL HORMONE; GHRELIN; GHRELIN RECEPTOR; GLIBENCLAMIDE; INCRETIN; INTERLEUKIN 6; NITRIC OXIDE; OBESTATIN; OBESTATIN, HUMAN;

ARTICLE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; FOOD INTAKE; HUMAN; OBESITY; VASCULAR ENDOTHELIUM; VASODILATATION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; GHRELIN; HUMANS; INCRETINS; OBESITY;

EID: 84908403521     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201402700314     Document Type: Article

References (32)

1. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: A systematic review and meta-analysis. JAMA 2013; 2:309:71-82.
2. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity among adults: United States, 2011-2012. NCHS data brief 2013; 1-8.
3. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303:235-41.
4. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-5.
5. Tesauro M, Cardillo C. Obesity, blood vessels and metabolic syndrome. Acta Physiol 2011; 203:279-86.
6. Campia U, Tesauro M, Cardillo C. Human obesity and endothelium-dependent responsiveness. Br J Pharmacol 2012; 16:561-73.
7. Schinzari F, Tesauro M, Rovella V, et al. Generalized impairment of vasodilator reactivity during hyperinsulinemia in patients with obesity-related metabolic syndrome. Am J Physiol Endocrinol Metab 2010; 299:E947-52.
8. Schinzari F, Tesauro M, Rovella V, et al. Leptin stimulates both endothelin-1 and nitric oxide activity in lean subjects but not in patients with obesity- related metabolic syndrome. J Clin Metab 2013; 98:1235-41.
9. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122:248- 56 e5.
10. Tharakan G, Tan T, Bloom S. Emerging therapies in the treatment of 'diabesity': beyond GLP-1. Tr Pharmacol Sci 2011; 32:8-15.
11. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: Testing and clinical relevance. Circulation 2007; 115:1285-95.
12. Vita JA, Keaney JF Jr. Endothelial function: A barometer for cardiovascular risk? Circulation 2002; 106:640-2.
13. Campia U, Tesauro M, Di-Daniele N, Cardillo C. The vascular endothelin system in obesity and type 2 diabetes: Pathophysiology and therapeutic implications. Life Sci 2014; 3:S0024-32.
14. Drexler H. Endothelial dysfunction: clinical implications. Progr Card Dis 1997; 39:287-324.
15. Tesauro M, Schinzari F, Iantorno M, et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005; 112:2986-92.
16. Kieffer TJ, Habener JF. The glucagone-like peptides. EndocrRev 1999; 20:876-913.
17. Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 19(308): 1132-41.
18. Hattori Y, Jojima T, Tomizawa A, et al. A glucagon- like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts antiinflammatory action in endothelial cells. Diabetol 2010; 53:2256-63.
19. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP- 1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007; 293:E1289-95.
20. Tesauro M, Schinzari F, Adamo A, et al. Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. Diabetes Care 2013; 36:683-9.
21. Ceriello A, Novials A, Canivell S, et al. Simultaneous glucagon-like peptide 1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes Care 2014; 3:25-30.
22. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. NEJM 2002; 346:1623-30.
23. Leite-Moreira AF, Soares JB. Physiological, pathological and potential therapeutic roles of ghrelin. Drug Disc 2007; 12:276-88.
24. Tesauro M, Schinzari F, Caramanti M, Lauro R, Cardillo C. Cardiovascular and metabolic effects of ghrelin. Curr Diab Rev 2010; 6:228-35.
25. Iantorno M, Chen H, Kim JA, et al. Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab 2007; 292:E756-64.
26. Tesauro M, Schinzari F, Rovella V, et al. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension 2009; 54:995-1000.
27. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005;310:996-9.
28. Agnew AJ, Robinson E, McVicar CM, et al. The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium- dependent NO signalling. Br J Pharmacol 2012; 166:327-38.
29. Specchio F, Saraceno R, Chimenti S, Nistico S. Management of non-melanoma skin cancer in solid organ transplant recipients. Int J Immunopath Pharmacol 2014; 27(1):21-24.
30. Muscoli C, Lauro F, Nistico S, et al. Olea Europea- derived phenolic products attenuate antinociceptive morphine tolerance: An innovative strategic approach to treat cancer pain. J Biol Reg Homeost Ag, 2014; 28(1): 117-28.
31. Specchio F, Carboni I, Chimenti S, Tamburi F, Nistico S. Cutaneous manifestations in patients with chronic renal failure on hemodialysis. Int J Immunopath Pharmacol 2014; 27(1): 1-4.
32. Chiricozzi A, Pitocco R, Saraceno R, Nistico SP, Giunta A, Chimenti S. New topical treatments for psoriasis. Exp Op Pharmacother 2014; 15(4):461-70.